Cargando…
Genetically engineered bacterium: Principles, practices, and prospects
Advances in synthetic biology and the clinical application of bacteriotherapy enable the use of genetically engineered bacteria (GEB) to combat various diseases. GEB act as a small ‘machine factory’ in the intestine or other tissues to continuously produce heterologous proteins or molecular compound...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606703/ https://www.ncbi.nlm.nih.gov/pubmed/36312915 http://dx.doi.org/10.3389/fmicb.2022.997587 |
_version_ | 1784818356007731200 |
---|---|
author | Liu, Yiting Feng, Jing Pan, Hangcheng Zhang, Xiuwei Zhang, Yunlei |
author_facet | Liu, Yiting Feng, Jing Pan, Hangcheng Zhang, Xiuwei Zhang, Yunlei |
author_sort | Liu, Yiting |
collection | PubMed |
description | Advances in synthetic biology and the clinical application of bacteriotherapy enable the use of genetically engineered bacteria (GEB) to combat various diseases. GEB act as a small ‘machine factory’ in the intestine or other tissues to continuously produce heterologous proteins or molecular compounds and, thus, diagnose or cure disease or work as an adjuvant reagent for disease treatment by regulating the immune system. Although the achievements of GEBs in the treatment or adjuvant therapy of diseases are promising, the practical implementation of this new therapeutic modality remains a grand challenge, especially at the initial stage. In this review, we introduce the development of GEBs and their advantages in disease management, summarize the latest research advances in microbial genetic techniques, and discuss their administration routes, performance indicators and the limitations of GEBs used as platforms for disease management. We also present several examples of GEB applications in the treatment of cancers and metabolic diseases and further highlight their great potential for clinical application in the near future. |
format | Online Article Text |
id | pubmed-9606703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96067032022-10-28 Genetically engineered bacterium: Principles, practices, and prospects Liu, Yiting Feng, Jing Pan, Hangcheng Zhang, Xiuwei Zhang, Yunlei Front Microbiol Microbiology Advances in synthetic biology and the clinical application of bacteriotherapy enable the use of genetically engineered bacteria (GEB) to combat various diseases. GEB act as a small ‘machine factory’ in the intestine or other tissues to continuously produce heterologous proteins or molecular compounds and, thus, diagnose or cure disease or work as an adjuvant reagent for disease treatment by regulating the immune system. Although the achievements of GEBs in the treatment or adjuvant therapy of diseases are promising, the practical implementation of this new therapeutic modality remains a grand challenge, especially at the initial stage. In this review, we introduce the development of GEBs and their advantages in disease management, summarize the latest research advances in microbial genetic techniques, and discuss their administration routes, performance indicators and the limitations of GEBs used as platforms for disease management. We also present several examples of GEB applications in the treatment of cancers and metabolic diseases and further highlight their great potential for clinical application in the near future. Frontiers Media S.A. 2022-10-13 /pmc/articles/PMC9606703/ /pubmed/36312915 http://dx.doi.org/10.3389/fmicb.2022.997587 Text en Copyright © 2022 Liu, Feng, Pan, Zhang and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Liu, Yiting Feng, Jing Pan, Hangcheng Zhang, Xiuwei Zhang, Yunlei Genetically engineered bacterium: Principles, practices, and prospects |
title | Genetically engineered bacterium: Principles, practices, and prospects |
title_full | Genetically engineered bacterium: Principles, practices, and prospects |
title_fullStr | Genetically engineered bacterium: Principles, practices, and prospects |
title_full_unstemmed | Genetically engineered bacterium: Principles, practices, and prospects |
title_short | Genetically engineered bacterium: Principles, practices, and prospects |
title_sort | genetically engineered bacterium: principles, practices, and prospects |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606703/ https://www.ncbi.nlm.nih.gov/pubmed/36312915 http://dx.doi.org/10.3389/fmicb.2022.997587 |
work_keys_str_mv | AT liuyiting geneticallyengineeredbacteriumprinciplespracticesandprospects AT fengjing geneticallyengineeredbacteriumprinciplespracticesandprospects AT panhangcheng geneticallyengineeredbacteriumprinciplespracticesandprospects AT zhangxiuwei geneticallyengineeredbacteriumprinciplespracticesandprospects AT zhangyunlei geneticallyengineeredbacteriumprinciplespracticesandprospects |